Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
- Conditions
- Schizophrenia
- Registration Number
- NCT04917302
- Lead Sponsor
- China Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria:<br><br> - Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia<br><br> - Are resistant to adequate treatments of at least two antipsychotics<br><br> - Remain symptomatic but without clinically significant fluctuation, while their<br> antipsychotic doses are unchanged for at least 3 months and will be maintained<br> during the period of the 12-week trial<br><br> - PANSS total score = 70<br><br> - Agree to participate in the study and provide informed consent<br><br>Exclusion Criteria:<br><br> - DSM-5 diagnosis of intellectual disability or substance (including alcohol) use<br> disorder<br><br> - History of epilepsy, head trauma, stroke, or serious medical or central nervous<br> system diseases (other than schizophrenia) which may interfere with the study<br><br> - Clinically significant laboratory screening tests (including blood routine,<br> biochemical tests)<br><br> - Pregnancy or lactation<br><br> - Inability to follow protocol
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of Positive and Negative Syndrome Scale (PANSS)
- Secondary Outcome Measures
Name Time Method Change of scales for the Assessment of Negative Symptoms (SANS) total score;Positive subscale, Negative subscales, and General Psychopathology subscale of PANSS;Clinical Global Impression;Global Assessment of Functioning;Hamilton Rating Scale for Depression;Quality of Life Scale;Cognitive function